The Application of Wide Pulse High Frequency Neuromuscular Electrical Stimulation in Disorders Associated With Motoneuron Hyperexcitability

NCT ID: NCT05908214

Last Updated: 2023-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the present project, the investigators aim at proposing innovative ways of investigating spinal motoneuron hyperexcitability to counteract the associated impairments by using wide pulse high frequency neuromuscular electrical stimulation (WPHF NMES) in various populations. The investigators will use WPHF NMES contractions as a model to gain insights into the mechanisms underlying muscle cramps, restless legs syndrome or stroke-induced spasticity as there is evidence that they share common underlying mechanisms. The investigators will then use WPHF NMES as a training modality to improve plantar flexor neuromuscular function in stroke patients by taking advantage of their motoneuronal hyperexcitability.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Cramp Restless Legs Syndrome Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Stroke patients in the training group will be compared to stroke patients in the control group.

Participants prone to cramps will be compared to healthy participants. Patients with restless legs syndrome will be compared to healthy participants.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stroke patients - training group

Participants in this group will take part in a 6-week WPHF NMES training period and plantar flexor neuromuscular function will be assessed before and after training.

Group Type EXPERIMENTAL

wide pulse high frequency neuromuscular electrical stimulation training

Intervention Type OTHER

Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks

stroke patients - control group

Participants in this group will keep their daily life activities for 6 weeks and plantar flexor neuromuscular function will be assessed before and after training.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

wide pulse high frequency neuromuscular electrical stimulation training

Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

STROKE PATIENTS:

* Diagnosis of first-ever stroke (ischemic or hemorrhagic) with unilateral motor deficits from at least 6 months. Stroke will have to be confirmed from medical records and/or radiological imaging (CT scan or MRI)
* Inadequate ankle control during gait defined as ankle dorsiflexion less than 5° during stance phase and 0° during swing phase; 0° = ankle neutral position)
* Passive range of motion of ankle dorsiflexion at least to neutral position
* Ability to walk at least 10 m with or without assistive devices
* Spasticity at the triceps surae (either soleus and/or gastrocnemii) considered as a Modified Ashworth Sore ≥1
* Being available for the study period and willing to participate
* No contraindication to neuromuscular electrical stimulation

Contraindications for stroke patients:

* Surface sensory loss of affected lower leg (defined as incapacity to feel the 60-g touch using the Semmes-Weinstein monofilament test)
* Patients unable to understand indications or to provide informed consent
* A history of orthopedic or other neurological disorders affecting walking function
* A history of surgery to correct drop foot (ankle fixation)
* Patients under antispastic medication (baclofen, tizanidine, tolperisone, benzodiazepines, dantrolene or botulinum toxin to the plantar flexor muscles in the last 6 months).

PEOPLE PRONE TO MUSCLE CRAMPS:

* Reporting nocturnal muscle cramps (the assessment will be done through a questionnaire)
* Not being treated for muscle cramps
* Being available for the study period and willing to participate
* No contraindication to neuromuscular electrical stimulation

PATIENTS WITH RESTLESS LEGS SYNDROME:

To be included in the study, RLS patients will have to satisfy the Diagnostic criteria for RLS published by the International Restless Legs Syndrome StudyGroup (IRLSSG). All five key clinical features are required for the diagnosis:

* An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. Sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs.
* The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
* The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
* The urge to move or unpleasant sensations are worse in the evening or night than during the day, or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.
* Symptoms are not solely accounted for by another medical or behavioral condition, such as leg cramps or habitual foot tapping.
* No contraindication to neuromuscular electrical stimulation

They will also have to satisfy the following criteria:

* Diagnosis of primary RLS corresponding to:

1. The presence of periodic limb movements
2. A dopaminergic treatment response
3. The presence of RLS in first-degree relatives
4. A lack of profound daytime sleepiness
* Being available for the study period and willing to participate

HEALTHY PARTICIPANTS:

* No neurological disease
* No contraindication to neuromuscular electrical stimulation
* Being available for the study period and willing to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss National Science Foundation

OTHER

Sponsor Role collaborator

University of Lausanne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nicolas Place

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bâtiment Synathlon, quartier UNIL-Centre

Lausanne, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nicolas Place, PhD

Role: CONTACT

+41216923806

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicolas Place, PhD

Role: primary

0216923806

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-01817

Identifier Type: -

Identifier Source: org_study_id